Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 130.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 130.
Type 2 Diabetes and Exercise Research Study 10-1393
To research the effects of an investigational drug on exercise capacity and blood vessel function​.​
Person 30-60 with Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure. Must not have smoked for at least one year and have a BMI between 25-39.9.
PI: Schauer, Irene
  • 720-848-6688
  • Katie.Rogers@ucdenver.edu
Volunteers with Chronic Kidney Disease needed for a Uric Acid Lowering Research Study 10-0625
To understand the effect of lowering serum uric acid levels on vascular function in individuals with CKD by comparing Allopurinol therapy and a placebo.
Persons 18+ with moderate chronic kidney disease (CKD stage III) with estimated glomerular filtration rates  between 30-60 mL/min/1.73m2
PI: Jalal, Diana
  • 303-724-2275
  • Emily.decker@ucdenver.edu
Research Study: "Anxiety Risk in Teens" 12-0424
To learn more about risk factors for anxiety in adolescents with cyclic vomiting syndrome.
Adolescents 13-18 who have been diagnosed with either an anxiety disorder or cyclic vomiting syndrome
PI: Tarbell, Sally
  • 720-777-6255
  • sally.tarbell@ucdenver.edu
Are you interested in learning about how your breast milk helps your baby grow? 12-0629
To find out how maternal size and diabetes status affect her breast milk To find out what unique parts of breast milk may affect how infants grow. To learn how to ensure infants receive the best nutrition possible
Women 20-35 who are at least 28 weeks into their pregnancy and planning on exclusively breastfeeding their infant for at least 4 months and delivering at University of Colorado Hospital.
PI: Krebs, Nancy
  • 303-724-3309
  • Bridget.Young@ucdenver.edu
Free Family Therapy for Youth with Mood Problems 11-1048
Helping youth and their families understand and cope with mood swings, develop plans for preventing moods from getting worse, communicate more effectively and solve family problems
  • Youth between 9-17 who has recently had significant mood swings, has at least one parent with bipolar disorder and does not abuse alcohol or substances. 
  • Must agree not to participate in family therapy with another provider for the first year.
PI: Schneck, Christopher
  • 303-492-1668
  • Anna.Frye@colorado.edu
Genital Herpes? 13-2122
This study will look at the body's immune response (how the body fights infection) to the onset of genital herpes.  1-2 study visits for blood draws over the course of 3 months.
  • 18+ years of age
  • Have developed an outbreak of genital herpes within the last 10 days.
PI: Levin, Myron
  • 303/724-2454
  • nancy.lang@ucdenver.edu
Seeking Children Ages 3 to 17 with NO History of Allergies, Eczema or Asthma HS-2581
The goal of this study is to determine why some individuals with atopic dermatitis are at increased risk for skin infections.
  • Between the ages of 3-17 
  • No history of allergies, eczema or asthma
PI: Leung, MD., Ph.D, Donald
  • 303-398-1409
  • lairsmithj@njhealth.org
Induction of Labor at 39 Weeks Pregnant versus Expectant Management 13-2085
Pregnant women are invited to participate in a research study which plans to learn more about whether coming to the hospital and having your labor started with medicine (ie., labor induction) at 39 weeks of pregnancy can improve the baby's health at birth when compared with waiting for labor to start on its own.
  • First pregnancy (no previous pregnancy beyond 20 weeks) 
  • Single baby (not twins or triplets) 
  • Planning to deliver vaginally and are at least 34 weeks pregnant 
  • Plan to deliver at University of Colorado Hospital or Denver Health Hospital
PI: Gibbs MD, Ronald
  • 303-724-2005
  • kathy.a.hale@ucdenver.edu or jocelyn.phipers@ucdenver.edu
Pregnant Participants Needed: A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus (GBS) Vaccine in Healthy Pregnant Women 13-3019
Pregnant women are invited to participate in a research study which plans to learn about antibody (substance produced by the body to fight disease) levels in mothers and infants whose mothers have received the GBS vaccine between 24-34 6/7 weeks of their current pregnancy.  the study will also look at antibody levels in mother's breast milk.
  • Healthy pregnant woman 18-40 years of age 24 0/7 through 34 6/7 weeks pregnant 
  • Planning to breastfeed for at least 90 days after delivery 
  • Plan to deliver at University of Colorado Hospital
PI: Gibbs MD, Ronald
  • 303-724-2005
  • sarah.schwartz@ucdenver.edu
Healthy Volunteers Needed 13-3002
The Department of Neurology is looking for healthy volunteers to participate in a research study examining blinking and spasms in people with Blepharospam compared to healthy controls
  • Between the ages of 50-80
  • Must not have any metal in your body
  • In good general health
PI: Berman, Brian
  • 303-724-5865
  • erika.shelton@ucdenver.edu
Healthy Volunteers Needed for a research study of drug levels in blood and hair. 13-0427
This study plans to learn more about how tenofovir and emtricitabine (Truvada) build up in cells in blood and hair. Participation will include two 12 week dosing periods separated by a 12 week washout period (total duration is 36 weeks). Eligible participants will be given the supply of medications for the study.
  • Subject is age 18 to 50 years 
  • Subject is ambulatory 
  • Subject is able to comply with directly observed dosing procedures, including use of audio-visual streaming technology 
  • Subject is able to give informed consent 
  • Subject has a minimum scalp hair length of 2 cm in the occipital region. 
  • Subject is NOT pregnant, planning to become pregnant, or currently breastfeeding
  • Subject is low risk for HIV-1 infection 
  • Subject does NOT have any active psychiatric illness(es), social condition(s), or alcohol/drug abuse 
  • Subject does NOT have history of non-traumatic, pathologic bone fractures 
  • Subject does NOT have any medical conditions that alter red blood cell kinetics 
  • Subject does NOT have any uncontrolled medical conditions that would interfere with the study conditions
  • Subject does NOT have contraindicated concomitant medications
PI: Anderson, Peter
  • 3037248296
  • ariel.hodara@ucdenver.edu
Overweight? Women with a BMI of 30-40 needed for a birth control research study!! 13-2665
The University of Colorado School of Medicine’s Department of OB/GYN is seeking healthy volunteers for a research study of a new birth control pill.
Eligible participants must:
  • Have a BMI 32-40 
  • Be 21-35 years old
  • Have regular menstrual cycles
PI: Teal, Stephanie
  • 303 724 5284
  • cricket.mchugh@ucdenver.edu
Research Participants Needed 14-0770
We are looking for healthy participants to serve as a standard for comparison when describing physical function outcomes before and during prosthetic rehabilitation.
Inclusion Criteria:
  1. 50-85 years of age. 
  2. Able to walk continuously without assistance (i.e., do not use a cane or walker) for 10 minutes and physically active (e.g., participate in recreational activities like walking, jogging, hiking). 
  3. No neurological, vascular or cardiac problems that limit function.
  4. Body mass inde.
PI: Christiansen, Cory
  • 303-724-9590
  • krista.m.sanchez@ucdenver.edu
Shingles Vaccine Clinical Research Trial 13-3192
This study will compare responses to two shingles vaccines - the current FDA approved shingles vaccine and an investigational shingles vaccine
  • 70-85 years of age
  • In general good health 
  • No prior history of shingles 
  • Have never received the shingles vaccine
PI: Levin, MD, Myron
  • 303/724-2454
  • nancy.lang@ucdenver.edu
Thinking About Starting a New Physical Activity Program? 14-0275
This study will examine psychosocial predictors of physical activity. Participants will become members of the Anschutz Health and Wellness Center and will complete a variety of questionnaires and two fitness assessments over 12 weeks. Most of the questionnaires are completed online.
  • 30-89 years of age
  • Able to read and understand English
  • Not participating in regular physical activity for the past 3 months
  • Joining the Anschutz Health and Wellness Center
  • No physical contraindications to physical activity
  • No existing diagnoses of cardiovascular disease
  • Not pregnant.
PI: Hooker, Stephanie
  • 303-724-8228
  • stephanie.hooker@ucdenver.edu
The Role of Gut Bacteria in the Development of Type 1 Diabetes 11-1144
The goal of the research is to better understand the role bacteria that live in the intestine in the development of type 1 diabetes
  • Patients diagnosed with type 1 diabetes in the last 6 months 
  • Subjects with islet autoantibodies 
  • Subjects who do not have islet antibodies and are first-degree relatives of patients with diabetes or subjects with islet antibodies
  • 1-45 years of age
PI: Zipris, Danny
  • 303-724-6820 or 303-724-6821
  • aimon.alkanani@ucdenver.edu or james.needell@ucdenver.edu
Do you have Parkinson's Disease? 11-1237
To explore the effects of different doses of endurance exercise in people with PD.​
Persons 40-80 who have been diagnosed with Parkinson's Disease and are not yet taking medication or plant to start medication within the next 6 months. You must be willing to begin the exercise program immediately or after a delay of 6 months and willing to do aerobic exercise on a treadmill.
PI: Schenkman, Margaret
  • 720-848-6376
  • Toby.Wellington@ucdenver.edu
Do you have Atopic Dermatitis (Eczema)? HS-2581
To study eczema
Males and Females between 3 and 80 who have atopic dermatitis or males and females between 8 months and 80 who have a history of, or an active case of eczema hereticum (wide-spread herpes skin infection along with atopic dermatitis.
PI: Leung, Donald
  • 303-398-1409
  • taylorp@njhealth.org
Better Control of Type 2 Diabetes May Decrease Your Risk for Cardiovascular Disease. 10-0644
To look at the use of an extended release formula of Exenatide compared to a placebo to maintain normal glucose levels. Ultimately to see better control of diabetes and a decrease in cardiovascular disease events.​
Person 18+ with Type 2 Diabetes and take no more than 2 diabetes medications with stale doses for the last 3 months. Must not have a planned or anticipated revascularization procedure, but may have a history of cardiovascular disease and must see your primary care physician at least twice a year.
PI: Rasouli, Neda
  • 303-399-8020 X2059
  • chantal.underkofler@ucdenver.edu
Are you a Non-smoking Adult between the ages of 45 and 85? HS-1883a
We are interested in learning more about smoking related lung disease, and need healthy non-smoking participants.
45-85 years old Non-Hispanic White or African American No smoking history No evidence of lung disease
PI: Bowler, Russ
  • 303-270-2566
  • FratelliC@NJHealth.org
Influenza Study 11-0826
Doctors at the National Institutes of Health are conducting a research study (IRC-004) to investigate whether treating the flu decreases the amount of virus we can detect in your nose, and to understand whether the change in the amount of virus is associated with changes in your symptoms.
Volunteers may be male or female and must: -be at least 18 years old -have a history of an influenza-like illness -have an onset of illness within the past 48 hours -test positive for influenza
PI: Barron, Michelle
  • 303-724-0712
  • graham.ray@ucdenver.edu
Alterations in Lung Microbiome in Acute and Chronic HIV Infection 09-0898
This is a prospective, observational cohort study. Three groups (A1, A2, and B) will be enrolled in parallel.
-Men and women >/= 18 years. -Willing to follow all research requirements -Willing to provide written informed consent -Group A1- acute HIV infection defined as a high risk HIV exposure within the prior 30 days, or recent HIV-1 seroconversion defined as those with a high risk HIV-1 exposure -Group A2- healthy controls: HIV-1 seronegative with no high risk HIV-1 exposure in the prior 30 days and no chronic medical illness -Group B- HIV-1 infection diagnosed by a previous positive antibody or PCR test have been recommended to initiate HAART by their health care provider You should not be in this study if you are a pregnant or planning to become pregnant.
PI: Campbell, Thomas
  • 303-724-0762
  • christine.griesmer@ucdenver.edu
Has your child been diagnosed with generalized anxiety disorder? 13-1967
to study sleep and brain activity
• between the ages of 12 & 18 • diagnosed with GAD OR • not diagnosed with any psychological disorders AND who are • right-handed • without orthodontic braces • not taking sleep medications
PI: Mullin, Benjamin
  • 720-777-8006
  • benjamin.mullin@ucdenver.edu
Volunteers needed to Participate in a Research Study about Rheumatoid Arthritis 01-675
The purpose of this study is to learn more about how rheumatoid arthritis develops by studying people who do not have rheumatoid arthritis. Your participation in this study will help us determine if certain genetic and environmental factors affect the chances of developing RA-related autoantibodies in absence of rheumatoid arthritis.
You may be eligible to participate in the study if: -You are at least 18 years old -You do NOT have Rheumatoid Arthritis (RA)
PI: Norris, Jill
  • 303-724-7510
  • Marie.Feser@ucdenver.edu
Restoring Insulin Secretion (RISE) 13-0122
The Children’s Hospital Colorado Clinical Translational Research Center and the National Institutes of Health are conducting a study. This study is aimed at testing whether early treatment is beneficial to kids with early type 2 diabetes and kids at high risk of diabetes.
10-19 years of age, Pubertal, Overweight, Fasting glucose: >90 mg/dl; Impaired glucose tolerance: >140 mg/dl; Pre-diabetes or diagnosed with diabetes for less than 6 months; Metformin
PI: Nadeau, Kristen
  • Susan Gross
  • susan.gross@childrenscolorado.edu
Participate in a Research Study at the University of Colorado. UC Denver is Conducting a Study on Back Pain and Spinal Manipulation at the Anschutz Medical Campus 10-1383
To study muscle activity during chiropractic spinal manipulations
1) 18-55 years of age 2) Male 3) Must have low back pain
PI: Davidson, Bradley
  • 303-871-2813
  • lowbackresearch@gmail.com
Have you experienced a preterm birth? 13-0409
If you participate, the information we learn from you will help us better understand how and why 1 out of 10 pregnancies in the US end in preterm birth.
1. Women ages 18-45 years old 2. willing to meet for 1-2 hours in a focus group setting 3. a mother of a baby who was born more than 3 weeks before your due date
PI: Santoro, Nanette
  • 303-724-2046
  • celeste.robledo@ucdenver.edu
Do You Smoke? 12-0181
To figure out how these lung substances work in people who drink too much alcohol, who usually smoke, compared to those who do not drink heavily, but who smoke.
Smoking and nonsmoking males
PI: Burnham, Ellen
  • 303-724-6081
  • Carrie.Higgins@ucdenver.edu
Parents or Legal Guardians of Children with Disabilities 12-1664
Assistive Technology Partners, University of Colorado, Anschutz Medical Campus, is performing a study investigating the impact Socially Assistive Robotics has on motor, communication and cognitive skills of children with disabilities.
Children between the ages of 18 months to 5 years of age Have Significant motor and communication disabilities/delays NOT been diagnosed with blindness or deafness They are without a seizure disorder or with a well-controlled seizure disorder They have been on stable medication regime for the past 12 weeks, if they are currently taking medication.
PI: Sandstrum, Jim
  • 303-315-1287
  • Jim.Sandstrum@ucdenver.edu
The Influence of Couples' Conversation on the Heart 13-2188
The purpose of the study is to examine the influence that conversations between married couples have on the functioning of the heart.
Married Christian couples who: • Have been married for at least 1 yr. • Both believe in prayer. • Are not currently taking heart medications. • Do not have heart problems. • Are not pregnant.
PI: Grigsby, Megan
  • 303-556-6020
  • couplesandheartstudy@gmail.com

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 18, items 1 to 30 of 511.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 18, items 1 to 30 of 511.
A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee. Sponsor Protocol No. 8-01. WIRB Protocol No.20100579
McCarty, Eric12-0796
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. WIRB Protocol No. 20140064
Lewis, Karl13-3079
Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression. Sponsor Protocol No, IM103177. WIRB Protocol No. 20132295
Wiseman, Alexander13-3123
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA. Sponsor Protocol No. R1033-SRC-1239. WIRB Protocol No.20131518
Schwartz, Robert13-3265
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation Sponsor Protocol No. AG120-C-002 WIRB Protocol No. 20140544
Gore, Lia14-0012
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation. Sponsor Protocol No. AG120-C-001. WIRB Protocol No. 20140421
Pollyea, Daniel14-0013
A Phase Ib dose escalation/randomized phase II multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Sponsor Protocol No. CBYL719X2104. WIRB Protocol No.20140692
Jimeno, Antonio14-0034
A safety study for MSB0010445 in combination with Stereotactic Body Radiation in advanced melanoma subjects following prior treatment with ipilimumab Sponsor Protocol No. EMR 062235-005 WIRB Protocol No. 20140683
Lewis, Karl14-0050
Phase 1 study of ONT-10, a liposomal MUC1 cancer vaccine, in patients with solid tumors. Sponsor Protocol No. ONT-10-001. WIRB Protocol No. 20140202
Borges, Virginia14-0063
Maintenance therapy with ONT-10, a liposomal MUC1 cancer vaccine, in patients who have previously received ONT-10. Sponsor Protocol No. ONT-10-002. WIRB Protocol No. 20140221
Borges, Virginia14-0064
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. Sponsor Protocol No. 18R5-002. WIRB Protocol No. 20140743
Diamond, Jennifer14-0065
International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen. Sponsor Protocol No. TED12414. WIRB Protocol No. 20120931
Gore, Lia14-0079
A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd- Sulfate) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)(SELECT-2) Sponsor Protocol No. D1532C0064 WIRB Protocol No. 20121812
Oton, Ana14-0084
A multicenter, randomized, double-blind, placebo-controlled phase III trial of tecemotide versus placebo in subjects with completed concurrent chemo-radiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Sponsor Protocol No. EMR-63325-021. WIRB Protocol No. 20140155
Oton, Ana14-0085
A RANDOMIZED, DOUBLE-BLIND TRIAL ASSESSING THE IMPACT OF METHOTREXATE DISCONTINUATION ON THE EFFICACY OF SUBCUTANEOUS TOCILIZUMAB WITH METHOTREXATE THERAPY. Sponsor Protocol No. ML28776. WIRB Protocol No. 20132070
Striebich, Christopher14-0087
Evaluation of Potential Allergenicity of New Soybean Varieties Sponsor Protocol No. Monsanto Soy Allergen WIRB Protocol No.20131161
Fleischer, David14-0097
A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer. Sponsor Protocol No. E-3810-II-02. WIRB Protocol No. 20140760
Camidge, David14-0100
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma (SUMIT) Sponsor Protocol No. D1344C00001 WIRB Protocol No.20141762
Lewis, Karl14-0108
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid Tumors. Sponsor Protocol No. PT-112-101. WIRB Protocol No. 20140867
Camidge, David14-0151
An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer Sponsor Protocol No. CA209026 WIRB Protocol No. 20140357
Camidge, David14-0243
A MULTICENTER PHASE 1A/1B ASCENDING DOSE STUDY OF DCC-2701 TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN PATIENTS WITH ADVANCED SOLID TUMORS Sponsor Protocol No. DCC-2701-01-001 WIRB Protocol No. 20142004
Leong, Stephen14-0244
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors. Sponsor Protocol No. M14-237. WIRB Protocol No.20140725
Weekes, Colin14-0251
Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis. Sponsor Protocol No. CFTY720D2306E1. WIRB Protocol No. 20140779
Corboy, John14-0289


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more